| 摘要 |
The present invention describes the use of agents that interact with with major histocompatibility complex (MHC) HLA class I molecules, such as beta2-microglobulin, or antibodies that bind to beta2-mcroglobulin, for the treatment and prevention of multiple myeloma and other types of cancer. The anti-cancer therapeutics of the present invention interact with MHC molecules on the surface of the tumor cell to increase apoptosis and inhibit cell growth and proliferation. For example, in an embodiment, anti-beta2-microglobulin antibodies inhibit the growth of multiple myeloma cells by over 90%. Thus, the present invention describes a new class of anti-cancer therapeutics and methods of use. |
